Identification of a novel resistance ALK p.(Q1188_L1190del) deletion in a patient with ALK-rearranged non-small-cell lung cancer

Moushumi Suryavanshi; Krushna Chaudhari; Shrinidhi Nathany; Vineet Talwar

doi:10.1016/j.cancergen.2021.03.006

Identification of a novel resistance ALK p.(Q1188_L1190del) deletion in a patient with ALK-rearranged non-small-cell lung cancer

Cancer Genet. 2021 Aug:256-257:48-50. doi: 10.1016/j.cancergen.2021.03.006. Epub 2021 Apr 4.

Authors

Moushumi Suryavanshi¹, Krushna Chaudhari², Shrinidhi Nathany¹, Vineet Talwar³

Affiliations

¹ Molecular Diagnostics, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi 110085, India.
² Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi 110085, India.
³ Rajiv Gandhi Cancer Institute and Research Centre, New Delhi 110085, India.

PMID: 33887694
DOI: 10.1016/j.cancergen.2021.03.006

No abstract available

Keywords: ALK p (Q1188_L1190del); ALK-rearranged adenocarcinoma of lung; Carcinoma; Ceritinib resistance; Lorlatinib; Must contain the gene(s) and cancer type (from NCI Thesaurus); Next-generation sequencing; Non–small-cell lung.

Publication types

Case Reports

MeSH terms

Adult
Aminopyridines / pharmacology
Aminopyridines / therapeutic use
Anaplastic Lymphoma Kinase / genetics*
Carcinoma, Non-Small-Cell Lung / diagnostic imaging
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / genetics*
Drug Resistance, Neoplasm / drug effects
Drug Resistance, Neoplasm / genetics*
Female
Gene Deletion*
Humans
Lactams / pharmacology
Lactams / therapeutic use
Lung Neoplasms / diagnostic imaging
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics*
Positron Emission Tomography Computed Tomography
Pyrazoles / pharmacology
Pyrazoles / therapeutic use

Substances

Aminopyridines
Lactams
Pyrazoles
ALK protein, human
Anaplastic Lymphoma Kinase
lorlatinib